---

Acute Kidney Injury (AKI)

Definition

• Rise in serum creatinine (sCr) by ≥0.3 mg/dL within 48 hours, OR
• Rise in sCr to ≥1.5 times baseline within 7 days, OR
• Urine output <0.5 mL/kg/hour for ≥6 hours

The term "Acute Kidney Disease" (AKD) was introduced by KDIGO to capture cases where creatinine rises evolve over periods longer than 7 days and thus do not meet the formal AKI definition. - NKF Primer on Kidney Diseases, 8e

---

KDIGO Staging

---

Epidemiology

• ~20-25% of hospitalized adults have an elevated serum creatinine
• Up to 45% of ED admissions present with elevated sCr
• 55-65% of ICU patients develop AKI
• Community-acquired AKI: annual incidence <1%
• Prerenal azotemia accounts for 40% of hospital-acquired and 60-70% of community-acquired AKI cases
• Intrinsic AKI is present in 5-6% of ED admissions and up to 60% of ICU patients
• Intrinsic AKI requiring dialysis has increased substantially over the past three decades
• Goldman-Cecil Medicine, p. 1241

---

Three Anatomic Categories

1. Prerenal AKI (60-70% of cases)

• True volume depletion: Limited oral intake, fever/sweating, burns, diarrhea, diuretics, hemorrhage
• Effective volume depletion: Heart failure, liver failure/cirrhosis, nephrotic syndrome
• Medications reducing GFR: NSAIDs, ACE inhibitors, angiotensin receptor blockers, cyclosporine, radiocontrast agents

• BUN:Creatinine ratio >20:1 (increased urea reabsorption due to low effective arterial volume)
• FENa <1% in oliguric patients (intact tubular sodium reabsorption)
• Rapidly reversible with volume repletion within hours
• Urinary biomarkers of tubular injury not particularly elevated

FENa can be influenced by diuretics; in such cases, FEurea <35% is more reliable. - NKF Primer, p. 346

2. Intrinsic AKI (25-40% of cases)

• Tubular cell injury (80-90% of intrinsic AKI):
  • Ischemic/ATN: Ischemia, reperfusion, inflammation, coagulation (e.g., sepsis, major surgery, cardiogenic shock)
  • Toxic ATN: Endogenous toxins (myoglobin, hemoglobin, uric acid crystals, calcium oxalate) or exogenous (radiocontrast, aminoglycosides, vancomycin, amphotericin B, cisplatin, tacrolimus, cyclosporine)
• Acute Interstitial Nephritis (5-10%): Drug-induced (sulfonamides, penicillins, cephalosporins, NSAIDs, PPIs, checkpoint inhibitors), infections (Legionella, leptospirosis, SARS-CoV-2), autoimmune (SLE, Sjögren's)
• Acute Glomerulonephritis (<5%): Rapidly progressive GN, vasculitis

3. Postrenal AKI (5-10% of cases)

• Men: Benign prostatic hypertrophy (most common), bladder outlet obstruction
• Both sexes: Nephrolithiasis, pelvic malignancy, retroperitoneal fibrosis, neurogenic bladder
• Children: Congenital anatomic abnormalities

---

Pathophysiology of AKI (ATN)

1. Depletion of ATP → loss of cell polarity → detachment of tubular epithelial cells
2. Cells form casts obstructing tubular flow → back-leak of filtrate
3. Intense afferent arteriolar vasoconstriction (tubuloglomerular feedback via macula densa)
4. Endothelial activation → inflammation, neutrophil and monocyte infiltration
5. Reparative phase involves upregulation of genes for cell-cycle regulation, growth factors (KIM-1, NGAL), and cytokines

---

Diagnosis and Evaluation

Serum Creatinine - Limitations

• Reflects GFR only at steady-state; there is a 24-72 hour lag before sCr stabilizes after an acute injury
• Influenced by age, sex, muscle mass, and catabolic state
• Volume resuscitation dilutes sCr, masking true AKI severity (the FACTT trial demonstrated fluid-corrected sCr identified more AKI cases)
• In the elderly and malnourished, lower creatinine generation means sCr rises more slowly even with severe injury

Urine Studies

Urinary electrolytes should not be used in isolation - they are influenced by diuretics, sepsis, cirrhosis, and the phase of AKI when obtained. - NKF Primer, p. 347

Novel Biomarkers

---

Management

General Principles (Goldman-Cecil Medicine, p. 1243)

"Treatments involve removal of offending stimuli, correcting any obstruction, and supportive care to address volume depletion and electrolyte disturbances."

1. Identify and Treat the Cause

• Discontinue nephrotoxins (NSAIDs, aminoglycosides, contrast, ACE inhibitors if prerenal)
• Relieve urinary obstruction (Foley catheter, ureteric stent, percutaneous nephrostomy)
• Treat sepsis aggressively (source control, antibiotics, hemodynamic support)
• Treat AIN with steroids when drug-induced and offending agent removed

2. Fluid and Hemodynamic Management

• Prerenal AKI: IV fluids (isotonic crystalloids preferred); target euvolemia
• Avoid fluid overload - associated with worse outcomes in AKI
• Vasopressors in septic shock to maintain MAP ≥65 mmHg
• Balanced crystalloids (e.g., lactated Ringer's) are preferred over normal saline to reduce hyperchloremic acidosis and AKI risk

3. Electrolyte Management

• Hyperkalemia: Dietary restriction, sodium bicarbonate, calcium gluconate (membrane stabilization), insulin/dextrose, kayexalate, dialysis if severe
• Metabolic acidosis: Sodium bicarbonate if pH <7.2 or HCO3 <15
• Hyperphosphatemia: Dietary restriction, phosphate binders
• Hyponatremia/hypervolemia: Fluid restriction

4. Nutritional Support

• Standard caloric needs (20-25 kcal/kg/day non-catabolic; 25-30 in hypercatabolic)
• Protein: 0.8-1.0 g/kg/day (non-dialysis); 1.0-1.5 g/kg/day if on RRT

5. Drug Dosing Adjustments

• Renally cleared drugs must be dose-adjusted (antibiotics, anticoagulants, antivirals)
• Avoid NSAIDs, contrast, aminoglycosides when possible

6. Renal Replacement Therapy (RRT)

• Acidosis refractory to medical management
• Electrolyte disturbance (hyperkalemia) not responding to treatment
• Ingestion/intoxication
• Overload (fluid overload refractory to diuretics)
• Uremic symptoms (encephalopathy, pericarditis, coagulopathy, nausea/vomiting)

• Intermittent Hemodialysis (IHD): Hemodynamically stable patients; more efficient solute removal
• Continuous RRT (CRRT): Hemodynamically unstable patients; preferred in ICU
• Peritoneal dialysis: Alternative when vascular access not available

---

Complications of AKI

---

Prognosis and AKI-to-CKD Transition

• About 1/3 of hospitalized patients with AKI resolve within 24 hours, ~60% by 48 hours, and ~70% by 72 hours
• ATN carries a higher risk of CKD progression than non-ATN AKI
• Severe AKI requiring dialysis carries ~40-60% in-hospital mortality in ICU settings
• Each episode of AKI independently increases the risk of CKD, ESRD, cardiovascular events, and all-cause mortality
• Long-term follow-up with nephrology is essential after hospitalized AKI

---

Prevention

• Identify high-risk patients early (CKD, elderly, diabetic, volume-depleted, septic)
• Minimize nephrotoxin exposure; use N-acetylcysteine + hydration for contrast nephropathy
• Optimize hemodynamics before major surgery
• Use balanced crystalloids rather than normal saline for resuscitation
• Biomarker-guided (TIMP-2 × IGFBP7) protocols may allow preventive care bundles in high-risk surgical patients

---

• Goldman-Cecil Medicine International Edition, Ch. 106 - Acute Kidney Injury, p. 1241-1243
• NKF Primer on Kidney Diseases, 8e, Ch. 31 - Acute Kidney Injury Definition, p. 346-348
• Brenner and Rector's The Kidney, 2-Volume Set - AKI Biomarkers and Pathophysiology chapters
• Sabiston Textbook of Surgery, 14e - KDIGO Criteria Table 26.4, p. 449
• Frameworks for Internal Medicine - AKI Categories, p. 448

---

Causes of AKI - In Detail with Rationale

---

CATEGORY 1: PRERENAL AKI (40-80% of all AKI)

Core Rationale

Normal Autoregulatory Defense (Why Prerenal AKI Has a Threshold Effect)

1. Myogenic reflex: Afferent arteriole dilates in response to reduced perfusion pressure
2. Prostaglandins (PGI2, PGE2): Vasodilate the afferent arteriole under hypoperfusion
3. Angiotensin II: Preferentially vasoconstricts the efferent arteriole to maintain glomerular capillary pressure
4. Tubuloglomerular feedback: Macula densa senses low solute delivery → afferent arteriole dilates → maintains GFR

---

Causes of Prerenal AKI with Rationale

A. True Hypovolemia (Reduced Circulating Blood Volume)

---

B. Reduced Cardiac Output (Effective Arterial Hypovolemia)

---

C. Decreased Effective Arterial Volume (Distributive States)

---

D. Impaired Renal Autoregulation (Drug-Induced Prerenal AKI)

• Normal state: Renal prostaglandins (PGI2, PGE2) play a minor role in renal blood flow
• Hypoperfused state: Prostaglandins become critically important for maintaining afferent arteriolar dilation
• NSAIDs block COX-1/COX-2 → prostaglandin synthesis inhibited → afferent vasoconstriction → GFR falls
• Risk is highest in elderly, CKD, CHF, cirrhosis, or volume-depleted patients

• Angiotensin II normally maintains GFR under hypoperfusion by constricting the efferent arteriole
• ACE-I/ARBs block this → efferent arteriole dilates → glomerular capillary hydrostatic pressure drops → GFR falls
• Critical scenario: Bilateral renal artery stenosis - GFR is entirely dependent on efferent vasoconstriction; ACE-I/ARB causes precipitous GFR loss
• Also important: combined NSAID + ACE-I use ("triple whammy" with diuretic) dramatically increases AKI risk

• Cause intense afferent arteriolar vasoconstriction → reduced GFR
• This is a hemodynamic (prerenal-type) effect, distinct from their chronic nephrotoxicity

SGLT-2 inhibitors lower intraglomerular pressure by reducing proximal tubule sodium reabsorption, but recent studies show a protective effect against AKI - probably through reduction in hyperfiltration injury and anti-inflammatory effects. - Harrison's Principles, 22e

---

CATEGORY 2: INTRINSIC (RENAL) AKI

Core Rationale

---

2A: TUBULAR INJURY - Acute Tubular Necrosis (ATN) - 80-90% of Intrinsic AKI

• They have the highest metabolic demand (ATP-intensive active transport)
• They exist in the most hypoxic zone of the kidney (renal medulla has a naturally low pO2)
• They cannot switch to anaerobic glycolysis under ischemia

---

i. Ischemic ATN

1. ATP depletion → failure of Na-K-ATPase → cells swell, lose polarity
2. Cytoskeletal disruption → loss of brush border → tubular cells detach into lumen
3. Detached cells + cellular debris form casts → tubular obstruction → raised intratubular pressure → backpressure on glomerulus → GFR falls
4. Backleak of filtrate across denuded, leaky tubular epithelium → net fluid absorption is impaired
5. Afferent arteriolar vasoconstriction (from tubuloglomerular feedback - macula densa senses increased distal solute delivery due to failed proximal reabsorption) → further reduces GFR
6. Inflammatory cascade: Neutrophils and monocytes infiltrate the interstitium → cytokine release (TNF-α, IL-1, IL-6) → endothelial injury → microvascular thrombosis → worsens medullary ischemia
7. Reactive oxygen species (ROS) from mitochondrial dysfunction cause lipid peroxidation, cell membrane damage, and apoptosis

"Transient ischemia alone in a normal kidney is usually not sufficient to cause severe AKI, as evidenced by the relatively low risk of severe AKI even after total interruption of renal blood flow during suprarenal aortic clamping or cardiac arrest." Prerenal azotemia and ischemic ATN represent a continuum. - Harrison's Principles, 22e

---

ii. Sepsis-Associated AKI (most common cause of ATN in ICU)

• Renal vasoconstriction: Activation of RAAS, sympathetic nervous system, vasopressin, and endothelin
• Paradox: In early sepsis, renal blood flow may actually be normal or even high, yet GFR falls - suggesting altered intrarenal microvascular distribution (shunting away from medullary tubules)
• Endothelial damage → increased leukocyte adhesion and migration → microvascular thrombosis → tubular ischemia
• Cytokine storm: TNF-α, IL-1, IL-6, IL-8 → direct tubular toxicity, increased permeability
• Reactive oxygen species from activated neutrophils and macrophages → oxidative tubular damage
• Sepsis may also cause AIN (see below)

---

iii. Exogenous Nephrotoxins

• Mechanism 1 - Renal medullary ischemia: Contrast causes intense intrarenal vasoconstriction via endothelin, adenosine, and reduced nitric oxide → medullary hypoxia (S3 segment and thick ascending limb most affected)
• Mechanism 2 - Direct tubular cytotoxicity: Contrast agents are directly toxic to tubular epithelial cells via reactive oxygen species and apoptosis
• Timeline: SCr rises at 24-48 hours, peaks at 3-5 days, typically resolves within 1 week
• Risk factors: CKD, diabetes, volume depletion, high contrast volume, heart failure, NSAID/ACE-I use
• Prevention: IV fluid hydration with isotonic saline before and after, minimize contrast dose, use iso-osmolar agents

• Freely filtered at glomerulus → concentrated in proximal tubular cells (via megalin receptor)
• Accumulate in lysosomes → phospholipidosis → lysosomal rupture → mitochondrial dysfunction → cell death
• Non-oliguric AKI in 10-30% of courses, even at therapeutic levels
• Onset: typically 5-7 days into therapy (can appear even after stopping)
• Causes hypomagnesemia (tubular Mg wasting) as an early sign
• Once-daily dosing reduces nephrotoxicity compared to multiple daily doses

• Binds ergosterol (and cholesterol) in tubular cell membranes → pores form → tubular cell lysis
• Also causes intense afferent arteriolar vasoconstriction → ischemia
• Causes distal RTA, hypokalemia, hypomagnesemia, and nephrotoxic ATN

• Tubular injury, especially when trough levels are high
• Can crystallize in tubules causing intratubular obstruction
• Synergistically nephrotoxic with aminoglycosides and piperacillin-tazobactam

• Enter proximal tubular cells via organic cation transporters
• Form platinum-DNA adducts in tubular cell nuclei → apoptosis and necrosis
• Non-oliguric AKI; also causes hypomagnesemia (tubular Mg wasting), hypokalemia

---

iv. Endogenous Nephrotoxins

1. Cast formation: Myoglobin precipitates with Tamm-Horsfall protein in acidic, concentrated urine → obstructive casts in distal tubules → tubular obstruction
2. Direct proximal tubular cytotoxicity: At pH ≤5.6, myoglobin dissociates into ferriheme + free iron → ferriheme causes lipid peroxidation → oxidative cell death in proximal tubules
3. Intrarenal vasoconstriction: Myoglobin scavenges nitric oxide (a potent renal vasodilator) → net vasoconstrictive effect; also activates endothelin-1, thromboxane A2, and RAAS

• Mechanism is analogous to myoglobin-induced ATN
• Causes: Transfusion reactions, G6PD deficiency, TTP/HUS, malaria, snake envenomation
• Hemoglobin cast formation in distal tubules + proximal tubular direct toxicity via heme iron

• Context: Tumor Lysis Syndrome (after cytotoxic therapy for high-burden tumors - lymphoma, leukemia) or spontaneous (Burkitt's, ALL)
• Massive cell death → huge purine load → uric acid overproduction → uric acid precipitates in collecting ducts and distal tubules (poorly soluble at acidic pH)
• Causes: tubular obstruction → anuria; also intrarenal vasoconstriction
• Treatment: rasburicase, allopurinol, IV hydration, urine alkalinization

• Light chains (Bence Jones proteins) filtered at glomerulus → co-precipitate with Tamm-Horsfall protein in distal tubules → obstruct tubules
• Light chains also directly toxic to proximal tubule cells (endocytosis → lysosomal injury)
• Volume depletion, contrast, hypercalcemia, and NSAIDs dramatically worsen myeloma AKI

• Ethylene glycol ingestion → oxalic acid → calcium oxalate crystals → tubular obstruction
• Also in primary oxaluria, after jejunoileal bypass

---

2B: ACUTE INTERSTITIAL NEPHRITIS (AIN) - 5-10% of Intrinsic AKI

• Mechanism: Drugs act as haptens or directly trigger a T-cell-mediated delayed hypersensitivity reaction against tubular antigens
• Key drugs:

• Mechanism: Direct infection or immune-complex deposition
• Legionella pneumophila, Leptospira, Streptococcus, Mycobacterium tuberculosis, CMV, EBV, SARS-CoV-2, Hantavirus

• Sjogren's syndrome, SLE, sarcoidosis (granulomatous AIN), tubulointerstitial nephritis-uveitis (TINU) syndrome, IgG4-related disease

---

2C: ACUTE GLOMERULONEPHRITIS - <5% of Intrinsic AKI

• Proliferation of mesangial, endothelial, or epithelial cells → physically narrows the capillary lumen
• Fibrin deposition → occludes capillary loops
• Inflammatory cells → release cytokines/ROS damaging the filtration barrier

---

2D: VASCULAR CAUSES - Large and Small Vessel Disease

Large Vessel Disease

Small Vessel and Microvascular Disease

---

CATEGORY 3: POSTRENAL AKI (5-10% of all AKI)

Core Rationale

Pathophysiology of Obstruction

1. Acute obstruction → ↑ intratubular pressure → opposes net filtration pressure → GFR falls
2. Phase 1 (0-2 hrs): Compensatory afferent arteriolar dilation (prostaglandin-mediated) → increased renal blood flow
3. Phase 2 (2-5 hrs): Efferent arteriolar vasodilation → reduced filtration pressure
4. Phase 3 (>5 hrs): Afferent arteriolar vasoconstriction (angiotensin II, thromboxane A2, endothelin) → marked reduction in RBF and GFR
5. Prolonged obstruction → tubular atrophy + interstitial fibrosis → permanent CKD

Causes by Level

• Crystal precipitation: Uric acid (tumor lysis), calcium oxalate (ethylene glycol), phosphate (bowel prep), acyclovir, sulfonamides, methotrexate, indinavir
• Myeloma proteins (see above)

• Nephrolithiasis (most common cause of bilateral ureteral obstruction in young patients)
• Retroperitoneal fibrosis (idiopathic or secondary to drugs - methysergide, beta-blockers; associated with AAA)
• Pelvic/retroperitoneal malignancy (cervical, bladder, prostate, lymphoma, metastases)
• Sloughed renal papillae (diabetes, analgesic nephropathy, sickle cell disease)
• Surgical ligation of ureter
• Blood clots

• Benign prostatic hypertrophy - most common cause of postrenal AKI in older men
• Prostate cancer
• Neurogenic bladder (diabetic autonomic neuropathy, spinal cord injury, MS)
• Anticholinergic drugs (tricyclics, antihistamines, antipsychotics) → bladder atony
• Bladder carcinoma
• Blood clots, bladder stones

• Urethral stricture (post-infectious, post-traumatic)
• Phimosis (in children)
• Obstructed urinary catheter (most preventable cause in hospital)

"Obstruction is an eminently reversible cause of AKI and should be considered in every patient with newly discovered azotemia." - Rosen's Emergency Medicine

---

Summary Table: Distinguishing the Three Categories

---

• Harrison's Principles of Internal Medicine, 22e (2025) - Chapter 321, Prerenal Azotemia and Ischemia/Nephrotoxin-Associated AKI
• Rosen's Emergency Medicine - Chapters 83 and 116 (Rhabdomyolysis)
• Goldman-Cecil Medicine International Edition - Chapter 106, Intrinsic AKI
• Frameworks for Internal Medicine - Chapter 33, AKI Categories
• Smith and Tanagho's General Urology, 19e - Postrenal Kidney Injury

---

The RIFLE Classification System

Background and Origin

---

The RIFLE Acronym - What Each Letter Means

---

Full RIFLE Criteria Table

---

Explaining Each Stage in Detail

R = Risk

"The first stratum provides the greatest sensitivity for diagnosing AKI." - Brenner and Rector's The Kidney

---

I = Injury

---

F = Failure

• ×3 rise = GFR has fallen by ~75% or more - the kidney retains barely a quarter of its filtration capacity
• sCr ≥4 mg/dL with acute rise ≥0.5 mg/dL - this absolute threshold catches patients with CKD who may not show a ×3 rise from their (already elevated) baseline but still have acute-on-chronic severe failure

• <0.3 mL/kg/h for >24 hours = severe oliguria (almost anuric over a full day)
• Anuria for >12 hours = complete cessation of urine production, which in the absence of obstruction indicates either severe tubular necrosis, renal cortical necrosis, or vascular occlusion

---

L = Loss

---

E = End-Stage Kidney Disease (ESKD)

1. KDIGO defines CKD as ≥3 months of impaired function/structure
2. Beyond 3 months of RRT dependence after an AKI event, spontaneous renal recovery is extremely unlikely
3. This marks the transition from acute/subacute to chronic kidney disease requiring indefinite renal replacement (dialysis or transplantation)

---

The Funnel Design - Why It's Shaped That Way

• Wide at the top (Risk): Large number of patients qualify → high sensitivity, lower specificity → good for early detection and population-level surveillance
• Narrow at the bottom (Failure): Fewer patients qualify → lower sensitivity, very high specificity → good for identifying the most severe cases reliably

"As proposed, the first stratum provides the greatest sensitivity for diagnosing AKI, whereas higher strata provide increasing specificity of diagnosis." - Brenner and Rector's The Kidney, 2-Volume Set

---

Mortality Correlation with RIFLE Grade

---

Key Diagnostic Rule - "Worst Criteria" Principle

---

What RIFLE Does NOT Include - Its Limitations

---

How RIFLE Led to AKIN and KDIGO

"KDIGO further refined the AKIN criteria and developed a method to address unknown baseline sCr values." - Current Surgical Therapy 14e

---

Pediatric RIFLE (pRIFLE)

---

Summary: Why RIFLE Matters

1. Standardization - replaced 35+ competing definitions with one consensus framework
2. Severity stratification - allows comparison of AKI severity across patients, studies, and populations
3. Outcome prediction - each RIFLE stage correlates with mortality, length of ICU stay, and need for dialysis
4. Early detection - the "Risk" stage was explicitly designed to enable preventive intervention before irreversible injury occurs
5. Historical foundation - RIFLE is the ancestor of both AKIN and KDIGO, which are now the clinical standards

---

• Brenner and Rector's The Kidney, 2-Volume Set - Table 29.2 and staging criteria
• Current Surgical Therapy 14e - ADQI, RIFLE, AKIN, KDIGO section with mortality data
• Morgan and Mikhail's Clinical Anesthesiology, 7e - Table 31-3 (RIFLE/AKIN/KDIGO comparison)
• Miller's Anesthesia, 10e - RIFLE Classification Scheme Table
• NKF Primer on Kidney Diseases, 8e - Fig. 31.1 RIFLE/AKIN/KDIGO systems

---

Causes of AKI

---

1. PRERENAL (60-70%)

Reduced renal perfusion - no structural damage - reversible with fluid/hemodynamic correction

---

2. INTRINSIC RENAL (25-40%)

Structural damage to kidney parenchyma - not immediately reversible

A. Tubular Injury / ATN (80-90% of intrinsic)

B. Acute Interstitial Nephritis / AIN (5-10%)

C. Glomerulonephritis (<5%)

D. Vascular Causes

---

3. POSTRENAL (5-10%)

Obstruction of urine outflow - must be bilateral (or single functioning kidney)

---

Quick Comparison: How to Distinguish Them

---

---

Causes of AKI - Complete Detail with Rationale

---

CATEGORY 1: PRERENAL AKI (60-70%)

Core Pathophysiologic Rationale

1. Myogenic reflex - afferent arteriole dilates when wall tension falls (low perfusion pressure)
2. Prostaglandins (PGI₂, PGE₂) - synthesized locally, keep afferent arteriole dilated under hypoperfusion
3. Angiotensin II - constricts the efferent arteriole, preserving glomerular capillary hydrostatic pressure when perfusion is low

---

1A. TRUE HYPOVOLEMIA

Gastrointestinal Losses

• Diarrhea also causes hyperchloremic metabolic acidosis which, combined with hypovolemia, synergistically worsens renal hypoperfusion
• Vomiting causes metabolic alkalosis + hypochloremia → paradoxically, the kidney reabsorbs HCO₃⁻ avidly and excretes Na⁺ - an exception where FENa may be high despite true hypovolemia

Hemorrhage

Burns

Diuretic Overuse

• Risk is highest in patients with CHF or cirrhosis given diuretics - these patients' kidneys depend on maximal RAAS-mediated sodium retention to maintain any effective circulating volume; diuretics undermine this
• Metolazone combined with furosemide can cause precipitous volume depletion

Insensible Losses

Third-Space Sequestration

---

1B. REDUCED CARDIAC OUTPUT (Cardiorenal Syndrome)

Myocardial Infarction / Cardiomyopathy / Heart Failure

1. RAAS activation → aldosterone → sodium and water retention → worsens edema
2. ADH release → free water retention → dilutional hyponatremia
3. Sympathetic activation → renal vasoconstriction → GFR falls
4. Reduced renal blood flow → ischemic tubular injury if prolonged

• Diuretics given to relieve congestion can worsen renal perfusion, raising creatinine - the clinical dilemma of "cardiorenal syndrome type 1"
• Every 10 mmHg drop in MAP from cardiac failure causes ~10% reduction in GFR

Cardiac Tamponade / Massive Pulmonary Embolism

---

1C. DECREASED EFFECTIVE ARTERIAL VOLUME (Distributive)

Hepatorenal Syndrome (HRS)

1. Portal hypertension (from cirrhosis, acute liver failure) → splanchnic vascular bed vasodilates
2. This splanchnic vasodilation is driven by excess nitric oxide production by endothelial cells in splanchnic vessels
3. Systemic circulation becomes "underfilled" (low effective arterial volume) despite total body volume excess
4. The kidney "reads" this as severe hypovolemia → maximal RAAS + SNS + ADH activation → intense renal vasoconstriction (endothelin, angiotensin II, vasopressin)
5. Renal blood flow falls dramatically → GFR → near zero
6. Crucially: the kidneys are structurally normal - if transplanted into a healthy recipient, they function perfectly. If a normal liver is transplanted into an HRS patient, the kidneys recover.

"Hepatorenal syndrome is a form of renal failure occurring in individuals with liver failure in whom there is no intrinsic morphologic or functional cause for kidney dysfunction." - Robbins Pathologic Basis of Disease

Nephrotic Syndrome

Sepsis (Distributive Shock)

Hypercalcemia (Cancer, Hyperparathyroidism)

---

1D. DRUG-INDUCED IMPAIRMENT OF RENAL AUTOREGULATION

NSAIDs (Including COX-2 Inhibitors)

• Under normal conditions: renal prostaglandins have minimal effect on GFR
• Under hypoperfusion (CHF, cirrhosis, volume depletion, CKD, elderly): PGI₂ and PGE₂ are critically upregulated to maintain afferent arteriolar dilation against intense angiotensin II-mediated vasoconstriction
• NSAIDs inhibit COX-1 and COX-2 → prostaglandin synthesis blocked → unopposed afferent arteriolar vasoconstriction → GFR collapses
• "High-risk triad": NSAID + ACE-I + diuretic = "Triple whammy" → very high AKI risk

• Acute interstitial nephritis (especially with nephrotic syndrome and minimal change disease simultaneously)
• Papillary necrosis (chronic use)
• Salt and water retention → worsens hypertension

ACE Inhibitors / ARBs

• Under normal perfusion: angiotensin II plays a minor role in GFR maintenance
• Under hypoperfusion: efferent arteriolar constriction by angiotensin II is the LAST LINE OF DEFENSE to maintain glomerular capillary hydrostatic pressure and GFR
• ACE-I/ARBs block this → efferent arteriole dilates → glomerular capillary pressure drops → GFR falls

• Both kidneys depend entirely on efferent constriction to maintain any GFR
• ACE-I or ARB → precipitous renal failure → presents as flash pulmonary edema
• Diagnosis: renal artery duplex ultrasound, CTA, or MRA

Cyclosporine / Tacrolimus (Calcineurin Inhibitors)

• Increasing endothelin-1 production
• Reducing prostaglandin and nitric oxide synthesis
• Activating sympathetic nervous system

Contrast Agents (CI-AKI)

1. Medullary ischemia: Contrast causes endothelin release + adenosine A1 receptor activation + reduced NO → intense intrarenal vasoconstriction particularly in the outer medulla → the S3 segment and thick ascending limb (highest O₂ demand, lowest O₂ supply) suffer ischemic injury
2. Direct tubular cytotoxicity: ROS generation from contrast → apoptosis and necrosis of proximal tubular cells

---

CATEGORY 2: INTRINSIC (RENAL) AKI (25-40%)

2A. ACUTE TUBULAR NECROSIS (ATN) - 80-90% of Intrinsic

Why the Proximal Tubule (S3/Pars Recta) and Medullary Thick Ascending Limb Are Vulnerable

• Cortical pO₂: ~50 mmHg
• Medullary pO₂: ~10-15 mmHg (nearly ischemic at baseline)

Ischemic ATN - Step-by-Step Molecular Mechanism

• Ischemia → oxidative phosphorylation fails → ATP depleted within minutes
• Na-K-ATPase fails → intracellular Na⁺ rises → cell swells
• Loss of cellular polarity: Na-K-ATPase redistributes from basolateral to apical membrane → tubule can no longer maintain Na⁺ gradient → more solute reaches macula densa

• Actin depolymerization → loss of brush border (seen as "muddy brown" casts in urine)
• Tight junction disruption → paracellular back-leak of filtrate
• Cell-cell adhesion molecules lost → tubular cells detach from basement membrane

• Detached cells + cellular debris + Tamm-Horsfall protein → form intratubular casts
• Cast obstruction → back-pressure on Bowman's capsule → glomerular filtration opposes its own pressure → GFR falls

• Injured proximal tubules fail to reabsorb Na⁺ → increased Na⁺ delivery to macula densa → tubuloglomerular feedback → afferent arteriolar vasoconstriction → further reduces GFR (a vicious self-amplifying cycle)

• Endothelial activation → increased ICAM-1, P-selectin, E-selectin → neutrophil adhesion and transmigration
• Neutrophils release: elastase, myeloperoxidase, superoxide → amplifies tubular injury
• Microvascular thrombosis (mediated by PAI-1 upregulation) → worsens medullary ischemia

• Re-oxygenation → burst of reactive oxygen species from xanthine oxidase and NADPH oxidase
• ROS causes lipid peroxidation, DNA strand breaks, mitochondrial permeability transition → cell death
• Complement activation → MAC (membrane attack complex) formation on tubular cells

• Surviving cells dedifferentiate → proliferate → redifferentiate → restore tubular integrity
• KIM-1, NGAL upregulated as repair signals
• Recovery typically 7-21 days for mild ATN; longer for severe

Sepsis-Associated ATN (Most Common ATN in ICU)

• Early sepsis is a "high-flow, low-resistance" state - renal blood flow may be normal or elevated, yet GFR falls. This suggests intrarenal maldistribution of blood flow (shunting from medulla to cortex)
• Cytokines (TNF-α, IL-1β, IL-6, IL-8): direct tubular toxicity, endothelial activation, impaired autoregulation
• LPS (lipopolysaccharide) binds TLR4 on tubular cells → NF-κB activation → inflammatory gene expression → tubular injury independent of ischemia
• Microvascular coagulopathy: fibrin microthrombi in glomerular capillaries + peritubular capillaries → ischemia
• Reactive nitrogen species (peroxynitrite from iNOS) → tubular cell mitochondrial damage
• Glycocalyx shedding from endothelium → increased microvascular permeability + coagulation activation

---

2B. EXOGENOUS NEPHROTOXINS - Detailed Mechanisms

Aminoglycosides (Gentamicin, Tobramycin, Amikacin, Streptomycin)

1. Filtered at glomerulus → binds to megalin receptor and anionic phospholipids on the brush border of S1 and S2 proximal tubular cells
2. Endocytosed into lysosomes → inhibits lysosomal phospholipases → phospholipidosis (lipid accumulation in lysosomes)
3. Lysosomal rupture → release of cathepsins → mitochondrial damage → impaired oxidative phosphorylation → ATP depletion → cell death
4. ROS generation from iron chelation

• Onset: 5-7 days (drug accumulates in cortex; cortical concentration can exceed plasma by 10-100x)
• Non-oliguric AKI (preserved urine output despite GFR decline - distal tubule function partially preserved)
• Hypomagnesemia (early sign - Mg wasting from tubular injury)
• Can occur even after stopping drug (cortical accumulation persists)
• Risk reduced with: once-daily dosing, drug level monitoring, adequate hydration

Vancomycin

• Direct tubular toxicity: enters proximal tubular cells via endocytosis → mitochondrial dysfunction → ROS generation → apoptosis
• Crystal deposition in tubular lumens → obstruction
• In high doses: endosomal accumulation → lysosomal membrane disruption
• Synergistic toxicity with aminoglycosides (additive tubular injury) and piperacillin-tazobactam (mechanism unclear but well-documented clinically)
• AKI risk correlates with: trough levels >15 mg/L, prolonged duration, concurrent nephrotoxins, prior CKD

Amphotericin B

1. Hemodynamic: Binds ergosterol (and cholesterol) in tubular cell membranes → pore formation → depolarizes cells → triggers tubuloglomerular feedback → intense afferent arteriolar vasoconstriction → medullary ischemia
2. Direct cytotoxicity: Pore formation in tubular cell membranes → uncontrolled ion fluxes → cell lysis

• Distal renal tubular acidosis (type 1) - impaired H⁺ secretion
• Hypokalemia (tubular K⁺ wasting)
• Hypomagnesemia
• Nephrogenic diabetes insipidus
• Progressive non-oliguric AKI

Cisplatin / Carboplatin

• Taken up into proximal tubular cells (S2 and S3 segments) via organic cation transporters (OCT2)
• Inside cell: forms platinum-DNA adducts → DNA strand breaks → p53 activation → apoptosis
• Also accumulates in mitochondria → inhibits oxidative phosphorylation → generates ROS → impairs ATP generation
• Causes tubular injury to both proximal and distal nephrons

• Non-oliguric AKI
• Hypomagnesemia (magnesium wasting - often persists long-term)
• Hypokalemia
• Hypocalcemia
• Dose-limiting toxicity: nephrotoxicity in ~30% without prophylaxis; intensive hydration (3-4 L/day) reduces but does not eliminate risk

Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4 Inhibitors)

• Remove normal T-cell suppression → hyperactivated T cells attack tubular cells
• AKI typically manifests as acute interstitial nephritis in ~3-5% of patients
• Average onset: 3-4 months after initiation (much later than classic drug-induced AIN)
• Risk factors: lower baseline GFR, concurrent PPI use, extrarenal immune-related adverse events
• Treatment: withdraw checkpoint inhibitor + high-dose corticosteroids; most (but not all) recover

Ifosfamide

• Produces nephrotoxic metabolite chloroacetaldehyde → tubular injury
• Specifically damages the proximal tubule → Fanconi syndrome:
  • Glycosuria (without hyperglycemia)
  • Aminoaciduria
  • Phosphaturia → hypophosphatemia
  • Type 2 (proximal) RTA
  • Polyuria
• Also causes hemorrhagic cystitis (mesna co-administration prevents this)

---

2C. ENDOGENOUS NEPHROTOXINS - Detailed Mechanisms

Myoglobin - Rhabdomyolysis

• Myoglobin filtered at glomerulus → at urine pH ≤5.6, myoglobin co-precipitates with Tamm-Horsfall protein → dense, obstructive casts in distal convoluted tubules
• Volume depletion concentrates the urine and acidifies it → ideal conditions for cast formation
• Rationale for treatment: IV isotonic saline dilutes myoglobin, and bicarbonate alkalinizes urine (pH >6.5) to prevent precipitation

• Myoglobin dissociates at acidic pH → ferriheme + free iron + globin
• Ferriheme: undergoes lipid peroxidation → lipid peroxides damage cell membranes
• Free iron (Fe²⁺): participates in Fenton reaction: Fe²⁺ + H₂O₂ → Fe³⁺ + OH⁻ + •OH (hydroxyl radical) → intense oxidative stress → tubular cell death

• Myoglobin scavenges nitric oxide (NO is a potent renal vasodilator) → unopposed endothelin-1, thromboxane A₂ activity → afferent vasoconstriction → ischemic overlay
• RAAS activation from volume depletion → further vasoconstriction
• Locally stimulated TNF-α, F2-isoprostanes → oxidant injury + vasoconstriction

Hemoglobin - Intravascular Hemolysis

1. Free hemoglobin (plasma) → filtered at glomerulus → distal tubular casts
2. Heme iron → Fenton reaction → ROS → proximal tubular oxidative injury
3. Hemoglobin scavenges NO → renal vasoconstriction
4. Hemoglobin dimers bind avidly to haptoglobin (rapidly saturated) → free hemoglobin in plasma → crosses glomerular filtration barrier

Uric Acid - Tumor Lysis Syndrome

• Massive cell death → release of purines (hypoxanthine, xanthine) → metabolized by xanthine oxidase → uric acid
• Uric acid supersaturation in renal tubules (especially collecting duct, distal tubule) → crystal precipitation
• At urine pH <5.5: uric acid is mostly un-ionized (pKa = 5.4) → highly insoluble → crystallizes
• Crystal obstruction → tubular inflammation → ATN

• Hyperphosphatemia → calcium phosphate crystals in tubules and microvasculature (at pH >7.0)
• Hypocalcemia from calcium-phosphate binding → tetany, seizures, arrhythmia
• Hyperkalemia from cell lysis → can be immediately life-threatening
• Crystal-independent uric acid toxicity: renal vasoconstriction, oxidative injury via ROS

Myeloma Cast Nephropathy ("Myeloma Kidney")

• Freely filtered Bence-Jones proteins → reabsorbed by proximal tubular cells via megalin → endosomal processing → released into cytoplasm
• Some κ and λ light chains have intrinsic physicochemical properties that directly injure lysosomes → lysosomal rupture → proximal tubular cell death
• Produces: Fanconi syndrome (glycosuria, phosphaturia, aminoaciduria, bicarbonaturia)

• Light chains reach the distal tubule at high concentrations → bind to Tamm-Horsfall protein under acidic, concentrated conditions → large, dense, fractured casts form
• Casts obstruct distal tubular lumens → retrograde pressure → GFR falls
• Inflammatory reaction: giant cells (activated macrophages) surround and engulf casts → local interstitial inflammation → additional injury
• Histology: pathognomonic fractured, fractured casts with pericast giant cell reaction

• Amyloidosis (AL type, λ chains): glomerular deposit → nephrotic syndrome → gradually failing GFR
• Light-chain deposition disease (κ chains): non-fibrillar deposits in GBM and mesangium → glomerulopathy
• Hypercalcemia-induced: afferent vasoconstriction + volume depletion + direct tubular toxicity

---

2D. ACUTE INTERSTITIAL NEPHRITIS (AIN) - Detailed Mechanism

Immunopathogenesis

1. Drug binds to tubular basement membrane or tubular cell surface antigen → acts as hapten
2. Antigen presented by MHC class II on macrophages to CD4⁺ T helper cells
3. Th1 cells: release IFN-γ → activate macrophages → granuloma formation (seen with rifampin, methicillin, thiazides)
4. Cytotoxic CD8⁺ T cells: directly kill tubular cells bearing drug-modified antigens (tubulitis on biopsy)
5. Tubulitis: lymphocytes migrating into and disrupting tubular epithelium - pathognomonic

• Drug acts as allergen → IgE production → mast cell + basophil degranulation → histamine + leukotrienes → eosinophil recruitment
• Explains: eosinophilia, rash, fever, elevated serum IgE

"Clinical evidence of hypersensitivity includes the latent period, eosinophilia and rash, the fact that the onset of nephropathy is not dose-related, and recurrence of clinical and pathologic manifestations after re-exposure to the same or a chemically related drug." - Robbins Pathologic Basis of Disease

• Classic triad (fever + rash + eosinophilia) present in only 10-30% of cases
• More common: unexplained AKI + sterile pyuria + WBC casts + mild proteinuria (<1 g/day)
• Flank pain (from renal capsule distension) in ~1/3
• Absence of classic triad does NOT exclude AIN
• Definitive diagnosis: renal biopsy showing interstitial edema + mononuclear infiltrate + tubulitis

---

2E. GLOMERULONEPHRITIS - Detailed Mechanisms

Type I RPGN - Anti-GBM Disease (Goodpasture's Syndrome)

• Autoantibodies against the α3 chain of type IV collagen in the glomerular basement membrane (and alveolar basement membrane)
• Antibodies bind → fix complement → recruit neutrophils → necrotizing injury to glomerular capillary walls
• Bowman's epithelial cells proliferate → form crescents (the histologic hallmark) → compress the glomerular tuft → GFR rapidly falls
• Linear IgG deposits on GBM (immunofluorescence)
• Pulmonary hemorrhage occurs when lung capillary basement membrane is also targeted (classic Goodpasture's)

Type II RPGN - Immune Complex

Type III RPGN - ANCA-Associated Vasculitis (Pauci-Immune)

• ANCA (anti-neutrophil cytoplasmic antibodies) bind surface-expressed PR3 (c-ANCA) or MPO (p-ANCA) on primed neutrophils
• ANCA-activated neutrophils adhere to endothelium → release proteases (elastase, proteinase 3) + ROS → necrotizing vasculitis of glomerular capillaries
• Fibrinoid necrosis of arterioles → capillary wall rupture → fibrin/cell crescent formation
• No or scanty immune deposits (pauci-immune = "few immune complexes") - distinguishing feature

---

2F. VASCULAR CAUSES - Detailed Mechanisms

TTP (Thrombotic Thrombocytopenic Purpura)

• ADAMTS13 (a metalloprotease) normally cleaves ultra-large von Willebrand factor (UL-vWF) multimers
• Deficiency of ADAMTS13 (congenital: Upshaw-Schülman syndrome; or acquired: autoantibody, usually IgG)
• UL-vWF multimers accumulate → spontaneously bind platelets under shear stress → platelet-rich microthrombi in arterioles and capillaries (especially brain and kidney)
• Red blood cells sheared by these microthrombi → schistocytes (fragmented RBCs)
• Classic pentad: MAHA + thrombocytopenia + neurological symptoms + fever + renal failure

"TTP is now defined as MAHA associated with ADAMTS13 activity of <5-10%." - Harrison's Principles, 22e

HUS (Hemolytic Uremic Syndrome)

• Shiga toxin (produced by E. coli O157:H7, Shigella dysenteriae) → binds Gb3 receptor on glomerular endothelial cells (highly expressed in children) → enters cell → inhibits protein synthesis → endothelial cell death
• Exposed subendothelial matrix → platelet activation + fibrin deposition → microvascular thrombosis predominantly in kidneys
• Triad: hemolytic anemia + thrombocytopenia + AKI (predominant, vs. TTP where neurological symptoms dominate)
• Bloody diarrhea prodrome (5-10 days before AKI) is the clinical hallmark

• Mutations in complement regulatory proteins (Factor H, Factor I, MCP/CD46) → uncontrolled complement activation on renal endothelium → TMA without Shiga toxin or ADAMTS13 deficiency
• Treatment: Eculizumab (anti-C5 monoclonal antibody)

Malignant Hypertension

• Extreme BP (usually >180/120 mmHg) → fibrinoid necrosis of arterioles: smooth muscle cells destroyed, plasma proteins (including fibrin) infiltrate the arterial wall
• Onion-skin proliferation of intima in larger vessels → stenosis
• Ischemic injury to glomeruli → rapidly progressive AKI
• RBC fragmentation from high shear in damaged vessels → microangiopathic hemolytic anemia (similar to TMA)

Atheroembolic AKI

• Cholesterol crystals embolize from atheromatous plaques in the aorta → lodge in renal interlobar arteries and arcuate arteries
• Triggers: aortic catheterization, angiography, aortic surgery, thrombolysis, anticoagulation (destabilizes plaques)
• Biconvex "needle-shaped" cholesterol crystal clefts on renal biopsy (crystals dissolve during processing, leaving empty clefts)
• Crystal deposition → eosinophilic granulomatous inflammation → intimal fibrosis → progressive ischemic nephropathy
• Subacute course (weeks-months) distinguishes it from acute embolic occlusion
• Systemic clues: livedo reticularis, blue toe syndrome, eosinophilia, hypocomplementemia, elevated ESR/CRP

---

CATEGORY 3: POSTRENAL AKI - Detailed Rationale

Pathophysiology of Obstruction - Phase Analysis

Crystal Nephropathy (Collecting Duct Level)

BPH - Why It Is the Leading Cause of Postrenal AKI in Older Men

• Retained urea acts as osmotic diuretic
• Natriuretic peptides accumulated during obstruction drive natriuresis
• Tubular concentrating ability impaired by prolonged hydronephrosis
• Patients require careful IV fluid replacement to prevent volume depletion (match urine output ml-for-ml with 0.45% saline)

---

MASTER TABLE: Rational Distinction of All Three Categories

---

• Harrison's Principles of Internal Medicine, 22e (2025) - Chapter 321 (Prerenal, Ischemic, Nephrotoxin AKI, TMA)
• Robbins, Cotran & Kumar Pathologic Basis of Disease - Ch. 20 (Drug-induced AIN, Myeloma Kidney, Hepatorenal)
• Comprehensive Clinical Nephrology, 7th Edition - Rhabdomyolysis, TLS, AIN, HRS
• Rosen's Emergency Medicine - Prerenal causes, Myoglobin mechanisms
• Frameworks for Internal Medicine - Prerenal causes and hemodynamic patterns